

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 October 2023 (26.10.2023)



(10) International Publication Number
WO 2023/205767 A3

(51) International Patent Classification:

A61K 35/761 (2015.01) A61P 9/00 (2006.01)
A61K 48/00 (2006.01) A61P 9/04 (2006.01)
C12N 15/63 (2006.01) A61P 21/00 (2006.01)
C12N 15/861 (2006.01)

(21) International Application Number:

PCT/US2023/066054

(22) International Filing Date:

21 April 2023 (21.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/333,798 22 April 2022 (22.04.2022) US

(71) Applicant: **SPACECRAFT SEVEN, LLC** [US/US]; 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US).

(72) Inventors: **HERZOG, Christopher Dean**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). **SACRAMENTO, Chester Bittencort**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). **RICKS, David**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). **PRABHAKAR, Raj**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US).

(74) Agent: **LAHERTY, Carol** et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: B-CELL LYMPHOMA 2-ASSOCIATED ANTHANOGENE 3 (BAG3) GENE THERAPY USING AAV VECTOR




Fig. 1

(57) Abstract: Provided herein is a gene therapy for BAG3 (B-cell Lymphoma 2-Associated Anthanogene 3), e.g., using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter, a cardiac troponin T (hTNNT2) promoter, a heat shock protein 70 (HSP70) promoter, or a ubiquitin C (UBC) promoter. The capsid may be an AAVrh.74 or AAV9 capsid or a functional variant thereof. In certain embodiments, the capsid is an AAVrh.74 capsid or functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the AAV vector, and other compositions and methods.

[Continued on next page]

WO 2023/205767 A3

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

30 November 2023 (30.11.2023)